Related Experiment Video
Updated: Aug 20, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
[Percutaneous coronary angioplasty in diabetic patients. Part II: hopes based on endovascular prosthesis]
F Warzée1, V Legrand, A J Scheen
1CHU Sart Tilman, Liège.
Insights
Diabetic patients have poorer outcomes from coronary artery revascularization, including percutaneous coronary angioplasty (PTCA) with bare-stents. Drug-eluting stents may offer improved management for these high-risk cardiac patients.
Area of Science:
- Cardiology
- Diabetology
- Interventional Cardiology
Background:
- Coronary artery revascularization yields less favorable results in diabetic patients compared to non-diabetics.
- Percutaneous coronary angioplasty (PTCA) in diabetics is linked to higher restenosis and cardiac events.
- Bare-metal stents reduce restenosis but are less effective in smaller vessels common in diabetic angiopathy.
Purpose of the Study:
- To evaluate the effectiveness of different coronary revascularization strategies in diabetic patients.
- To compare outcomes of PTCA with bare-metal stents versus coronary artery bypass graft (CABG) in diabetics.
- To explore the potential benefits of drug-eluting stents (DES) for diabetic patients with coronary heart disease.
Main Methods:
- Review of outcomes from coronary revascularization procedures in diabetic and non-diabetic populations.
- Analysis of restenosis rates and cardiac morbidity/mortality associated with PTCA and stenting.
- Consideration of data from the Arterial Revascularization Therapy Study (ARTS).
Main Results:
- Diabetic patients exhibit a worse prognosis even with PTCA and bare-metal stents compared to non-diabetics.
- Bare-metal stent efficacy diminishes in smaller coronary vessels, a frequent issue in diabetic patients.
- The ARTS trial highlights poorer outcomes for diabetics undergoing PTCA with bare-stents versus CABG.
Conclusions:
- Current revascularization strategies, including PTCA with bare-metal stents, are suboptimal for diabetic patients.
- Drug-eluting stents, with their pharmacological agents to prevent restenosis, present a promising alternative.
- DES may significantly improve the management and prognosis of coronary heart disease in the diabetic population.
Abstract:
Coronary artery revascularization procedures provide less favourable results in diabetic patients than in non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated with a higher rate of restenosis and recurrence of cardiac morbidity and death. In diabetic patients, PTCA should, if possible, be combined with a stent. Bare-stents allow to reduce approximately by half the risk of restenosis, but unfortunately their efficacy decreases as the vessel diameter decreases, a common finding among diabetic patients with angiopathy. ARTS ("Arterial Revascularization Therapy Study") recently showed that diabetic patients have a worse prognosis even when bare-stents are combined with PTCA as compared to non-diabetic subjects and as compared to diabetic patients treated with coronary artery bypass graft. These results open new perspectives in favour of the use of drug-eluting stents containing pharmacological agents capable of preventing restenosis. Such new stents might improve the management of diabetic patients with coronary heart disease.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease IV: Nursing Management
Diabetic Foot Ulcer
Diabetic Retinopathy
